Cargando…
Development and Optimization of Bifunctional Fusion Proteins to Locally Modulate Complement Activation in Diseased Tissue
Sustained complement activation is an underlying pathologic driver in many inflammatory and autoimmune diseases. Currently approved anti-complement therapies are directed at the systemic blockade of complement. Consequently, these therapies provide widespread inhibition of complement pathway activit...
Autores principales: | Fahnoe, Kelly C., Liu, Fei, Morgan, Jennifer G., Ryan, Sarah T., Storek, Michael, Stark, Ellen Garber, Taylor, Fred R., Holers, V. Michael, Thurman, Joshua M., Wawersik, Stefan, Kalled, Susan L., Violette, Shelia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244803/ https://www.ncbi.nlm.nih.gov/pubmed/35784298 http://dx.doi.org/10.3389/fimmu.2022.869725 |
Ejemplares similares
-
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction
por: Girardi, Guillermina, et al.
Publicado: (2006) -
Mapping the Complement Factor H-Related Protein 1 (CFHR1):C3b/C3d Interactions
por: Hannan, Jonathan P., et al.
Publicado: (2016) -
Specific Inhibition of Complement Activation Significantly Ameliorates Autoimmune Blistering Disease in Mice
por: Mihai, Sidonia, et al.
Publicado: (2018) -
Complement and autoimmunity: new insights into old questions
por: Holers, VM, et al.
Publicado: (2004) -
Antiphospholipid antibodies harness innate effectors, neutrophils and an alternative pathway of complement, to induce fetal damage
por: Salmon, J, et al.
Publicado: (2003)